NCT07534033RecruitingPhase 2
Phase II Clinical Study of Probiotic LR607 in Patients With Non-Small Cell Lung Cancer
Probiotics With High Expression of DL-peptidase (LR607) Can Enhance the Efficacy of Chemoradiotherapy in Resectable Stage IIA-IIIB Non-small Cell Lung Cancer: a Single-arm, Open-label, Multicenter, Phase II Clinical Trial
Source: ClinicalTrials.gov · Last updated 29 Oct 2026
Brief summary (registry, in English)
The goal of this clinical trial is to understand whether Lactobacillus rhamnosus LR607 can enhance neoadjuvant chemoimmunotherapy for adult patients with non-small cell lung cancer. It will also evaluate the safety of LR607. The main questions it aims to answer include: Can LR607 improve the major pathological response of neoadjuvant chemoimmunotherapy? What is the relationship between LR607 combined with neoadjuvant chemoimmunotherapy and treatment-related adverse reactions? What changes occur in the gut microbiota composition at the species level and gut metabolites of subjects after LR607 treatment? Participants will: Take LR607 daily for 3 months Visit the hospital for check-ups and examinations every month Record their pathological response, tumor recurrence, and treatment-related adverse reactions
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 46 (estimated)
- First submitted
- 11 Dec 2025
- Start date
- 6 Dec 2025
- Primary completion date
- 23 Dec 2026
- Lead sponsor
- Zhujiang Hospital
- Diseases
- Lung cancer
- NCT number
- NCT07534033
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 46
- From 6 Dec 2025 to the primary completion date, 23 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Including active autoimmune diseases
- Interstitial lung disease
- Presence of other malignancies
- History of immunotherapy
- Active infection
- Pregnancy or drug allergies
Other
- Recent use of immunosuppressants
Who the study is looking for
- Histologically confirmed newly diagnosed patients
- ECOG performance status 0-1
- Age ≥18 years
- Measurable lesions (RECIST v1.1)
- Organ function meeting the requirements for chemotherapy and immunotherapy.
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Zhu Jiang Hospital of Southern Medical University Coordinator of this site? Confirm its status | Guangzhou | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.